About Ribosyldihydronicotinamide dehydrogenase [quinone]
Ribosyldihydronicotinamide dehydrogenase [quinone] (NQO2) is a protein
from Homo sapiens identified by UniProt accession
P16083, 231 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Ribosyldihydronicotinamide dehydrogenase [quinone] |
| UniProt accession | P16083 |
| Gene | NQO2 |
| Organism | Homo sapiens |
| Length | 231 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (110)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.38
- protein measurement · score 0.37
- neurodegenerative disease · score 0.37
- urinary metabolite measurement · score 0.29
- specific language impairment · score 0.09
- 7q11.23 microduplication syndrome · score 0.07
- Monoamine oxidase A deficiency · score 0.07
- schizophrenia · score 0.06
- microangiopathy and leukoencephalopathy, pontine, autosomal dominant · score 0.06
- reticulocyte count · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P16083-F1 | alphafold | PREDICTED | 98.07 | — |
Amino-acid sequence (231 residues)
MAGKKVLIVY AHQEPKSFNG SLKNVAVDEL SRQGCTVTVS DLYAMNLEPR ATDKDITGTL SNPEVFNYGV ETHEAYKQRS LASDITDEQK KVREADLVIF QFPLYWFSVP AILKGWMDRV LCQGFAFDIP GFYDSGLLQG KLALLSVTTG GTAEMYTKTG VNGDSRYFLW PLQHGTLHFC GFKVLAPQIS FAPEIASEEE RKGMVAAWSQ RLQTIWKEEP IPCTAHWHFG Q
Explore Ribosyldihydronicotinamide dehydrogenase [quinone] with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets